Juan Jose Guerra Londono

Dr. Juan Jose Guerra Londono

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
CGCarlos E Guerra-Londono
Carlos E Guerra-Londono
CTCarlos Alberto Gomez Tarazona
Carlos Alberto Gomez Tarazona
JSJ. A. Sánchez-Monroy
J. A. Sánchez-Monroy
OHOlivia Heppell
Olivia Heppell
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
RSRupen Shah
Rupen Shah

1 October 2024 in Renal Failure
Verified
Journal Article
Open access
RWRyan Wong
Ryan Wong
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
AMArun Muthukumar
Arun Muthukumar
NCNicolas Cortes-Mejia
Nicolas Cortes-Mejia
DBDiana Fernanda Bejarano-Ramirez
Diana Fernanda Bejarano-Ramirez
JCJuan Cata
Juan Cata
Partial nephrectomies are associated with an increased risk of acute kidney injury (AKI), but dexmedetomidine administration may improve renal outcomes. We hypothesized that intraoperative dexmedetomidine administration would be associated with a decrease in AKI development in patients undergoing unilateral partial nephrectomy. In this retrospective study, adult patients who underwent unilateral partial nephrectomy from April 2016 to October 2023 were included. Exclusion criteria were a history of end-stage renal disease, ineligible procedures (i.e., aborted procedure, conversion to radical nephrectomy, surgery on a horseshoe kidney), and reoperation within three days of the initial nephrectomy. Patients were categorized according to whether they received intraoperative dexmedetomidine. The primary outcome was AKI incidence within three days of surgery; AKI was defined according to the Kidney Disease Improving Global Outcomes definition. Propensity score matching (PSM) was conducted to account for potential confounders (age, body mass index, sex, American Society of Anesthesiologists score, final surgical approach, clamping-related ischemia for >15 min). We included 1,632 patients; 214 received dexmedetomidine and 1,418 did not. Before PSM, the AKI rate was 31.2% in patients who received dexmedetomidine and 25.7% in patients who did not (p = 0.081). After PSM, the AKI rate was 31.3% in patients who received dexmedetomidine and 27.6% in those who did not (p = 0.396). The post-PSM odds ratio for AKI following dexmedetomidine administration during unilateral partial nephrectomy was 0.910 (95% CI: 0.585-1.142; p = 0.677). Intraoperative dexmedetomidine was not associated with a reduction in postoperative AKI incidence or severity after unilateral partial nephrectomy.

9 May 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
RWRyan Wong
Ryan Wong
RPRaj G. Patel
Raj G. Patel
NCNicolas Cortes-Mejia
Nicolas Cortes-Mejia
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
HHHuang Huang
Huang Huang
JCJuan Cata
Juan Cata

12 June 2025 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
ESEric Slawka
Eric Slawka
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
RHRachel S Hicklen
Rachel S Hicklen
SSSohan Lal Solanki
Sohan Lal Solanki
DCDaniel Cukierman
Daniel Cukierman
JCJuan Cata
Juan Cata
Background and Aims: Open access (OA) publishing improved the reach of scientific discoveries, particularly among researchers in lower-income countries. However, OA publishing still has a global imbalance. This bibliometric analysis evaluates anaesthesia OA journals to explore geographical and economic disparities in publication volume. Methods: We queried the Directory of Open Access Journals for OA anaesthesia-related journals between 2014 and 2024. Data from the included journals were analysed using Scopus, from which we extracted the year of publication and the corresponding author’s affiliation. Additional metrics were obtained from each journal website. Countries were then categorised by income level and geographical region. Results: Thirty-four anaesthesiology OA journals were analysed, encompassing 27,634 publications from 120 countries. The leading contributors were India (23.96%), the USA (14.98%) and China (6.54%). Low-income countries accounted for 0.37% of total publications, followed by upper-middle-income (17.97%), lower-middle-income (29.07%), and high-income (52.54%) countries. The geographical distribution of publication volume was as follows: Southeast Asia (25.38%), Europe (23.18%), Western Pacific (18.92%), Americas (23.91%), Eastern Mediterranean (8.03%) and Africa (0.59%). Nineteen journals required a mean article processing charge (APC) of US $2,164.89, accounting for 51.89% of the total publications. India ranked first in non-APC journals, while the USA led in APC journals . Conclusion: While OA publishing enhances accessibility for readers, it still presents challenges for authors, particularly in economically disadvantaged countries. Significant geographical and economic disparities exist in OA publication volume, likely due to limited investment and structural barriers in lower-income countries.

23 December 2023 in Current Anesthesiology Reports
Verified
Journal Article
Closed access
PDF file
DCDaniel S. Cukierman
Daniel S. Cukierman
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
JCJuan Cata
Juan Cata

2 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NCNicolas Andres Cortes-Meja
Nicolas Andres Cortes-Meja
JLJuan Jose Guerra Londono
Juan Jose Guerra Londono
TITarikul Islam
Tarikul Islam
HLHeather A. Lillemoe
Heather A. Lillemoe
GOGavin Ovsak
Gavin Ovsak
JCJuan Cata
Juan Cata
Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery. Methods: Adults (≥18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions. Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups. Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.